Upregulation of long noncoding RNA MRCCAT1 predicts poor prognosis and functions as an oncogene in glioma.

OBJECTIVE:This study aimed to investigate the expressions, clinical significances, roles, and mechanism of action of MRCCAT1 in glioma. PATIENTS AND METHODS:The expression of MRCCAT1 in 103 glioma tissues with different grades and 21 normal brain tissues was measured by qPCR. The prognostic value of MRCCAT1 was investigated by Kaplan-Meier survival analysis. The biological roles of MRCCAT1 on glioma cell proliferation were assessed by Glo cell viability assays and ethynyl deoxyuridine incorporation assays. The roles of MRCCAT1 on glioma cell migration were evaluated by transwell assays. The effects of MRCCAT1 on p38-MAPK signaling were assessed by Western blot. RESULTS:MRCCAT1 is upregulated in glioma tissues and positively associated with glioma grades. Increased expression of MRCCAT1 confers poor prognosis of glioma patients independent of glioma grades. Ectopic expression of MRCCAT1 promotes glioma cell proliferation and migration. Knockdown of MRCCAT1 inhibits glioma cell proliferation and migration. Mechanistically, we found that MRCCAT1 activates p38-MAPK signaling in glioma. CONCLUSIONS:MRCCAT1 is upregulated in glioma. Increased expression of MRCCAT1 predicts poor outcome of glioma patients. MRCCAT1 promotes glioma cell proliferation and migration via activating p38-MAPK signaling. MRCCAT1 may be a potential prognostic biomarker and therapeutic target for glioma.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}